bespark*bio is a privately held biotech start-up, offering bespoke process development for novel biotherapeutics such as viral vectors, bionanoparticles (VLPs and exosomes), and biologics (monoclonal antibodies).
We deliver robust, phase-appropriate and scalable processes, enhance development efficiency and significantly de-risk development activities for our clients.
R&D:Our advanced process development combines best-in-class bioprocessing expertise and state-of-the-art technology with contemporary digitalization and machine-learning approaches: Pre-developed modular process building blocks, which can seamlessly be integrated into comprehensive process streams and entire processes, serve as launch pads for swift and flexible customization tailored to our clients´ needs. Utilizing process simulation and hybrid modeling, we optimize processes and improve efficiency. The result? Accelerated development timelines, enhanced process understanding, minimized risk, and reduced costs.
Services:We drive our clients’ process development projects, striking the perfect balance between quality, cost, and speed. Our comprehensive suite of services is tailored to advance novel biotherapeutics at every stage: - Strategy development: CMC roadmaps & development plans, Quality by Design support, vector design - Process design, development & optimization: Upstream, downstream & end-to-end processes, process characterization, cell line development & optimization - Development and Implementation of process analytics: Analytical release & characterization plans, particle characterization, impurity profiles, Process Analytical Technology tools - GMP Support: Pre-established GMP Alliances, seamless technology transfer, manufacturing oversight
Muthgasse 11/2
Vienna
Vienna
Contact: Matthias Müllner, CEO
Telephone: +43 650 3685292
Email: matthias.muellner@bespark.bio
Website